References
- Wimazal F, Krauth M T, Vales A, Böhm A, Agis H, Sonneck K, et al. Immunohistochemical detection of VEGF in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leuk Lymphoma 2006; 47: 451–460
- Estey E H. Modulation of angiogenesis in patients with myelodysplastic syndrome. Best Pract Res Clin Haematol 2004; 17: 623–639
- Aguayo A, Giles F, Albitar M. Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk Lymphoma 2003; 44: 213–222
- Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci P F, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999; 81: 1398–1401
- Korkolopoulou P, Apostolidou E, Pavlopoulos P M, Kavantzas N, Vyniou N, Thymara I, et al. Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia 2001; 15: 1369–1376
- Mesa R A, Hanson C A, Rajkumar S V, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000; 96: 3374–3380
- Mesa R A, Hanson C A, Li C Y, Yoon S Y, Rajkumar S V, Schroeder G, Tefferi A. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood 2002; 99: 4131–4137
- Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, Fischer U, et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 2005; 23: 1109–1117
- Moehler T M, Ho A D, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003; 45: 227–244
- Bellamy W T, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427–1434
- Mangi M H. Misleading information about ALIP and VEGF in myelodysplasia. Blood 2001; 98: 1272–1273
- Gore S D. Inhibitors of signaling in myelodysplastic syndrome. Best Pract Res Clin Haematol 2004; 17: 613–622
- Giles F J, Stopeck A T, Silverman L R, Lancet J E, Copper M A, Hannah A L, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003; 102: 795–801
- Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann O G, O'Farrell A M, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 986–993
- Roboz G J, List A F, Giles F, Rae P E, Dugan M H, Greenberg J, et al. Phase I trial of PTK787/ZK 222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases in acute myeloid leukemia and myelodysplastic syndrome. Blood 2002; 100: 337
- Gotlib J, Jamieson C HM, List A, Cortes J, Albitar M, Sridhar K, et al. Phase II study of bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS): preliminary results. Blood 2003; 102: 425